2025
Small Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Original ResearchThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.
2024
Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers
Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.Peer-Reviewed Original ResearchB-cell maturation antigenRefractory myelomaAnti-BCMABispecific antibodiesInternational Myeloma Working Group Uniform Response CriteriaInstitutional experienceWinship Cancer Institute of Emory UniversityCAR-T cell therapyBispecific T-cell engagerSignificant tumor burdenT-cell engagersDecreased performance statusWinship Cancer InstituteRate of gradeLimited treatment optionsStatistically significant differenceMedian PFSPretreated patientsCAR-TMedian followResponse criteriaTumor burdenPretreated populationDose reductionMaturation antigenReal-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)
Theprungsirikul P, Wang R, Merl M, Wang S, Neparidze N. Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN). Blood 2024, 144: 3775. DOI: 10.1182/blood-2024-201603.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsT-cell-redirecting therapiesProgression free survivalRelapsed/Refractory Multiple MyelomaCytokine release syndromeLines of therapyReal-world treatment patternsMultivariate logistic regression modelExtramedullary diseaseOverall survivalTreatment patternsHazard ratioSevere cytopeniaT cellsResponse durationSevere infectionsAssess factors associated with overall survivalLogistic regression modelsInternational Myeloma Working Group criteriaAssociated with progression free survivalFactors associated with overall survivalHigher CRSMedian progression free survivalMedian time to progressionBispecific T-cell engagerNovel immunotherapeutics against LGR5 to target multiple cancer types
Chen H, Mueller N, Stott K, Kapeni C, Rivers E, Sauer C, Beke F, Walsh S, Ashman N, O’Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken S, Hoare M, Mair R, Serrao E, Brenton J, Garcia-Gimenez A, Richardson S, Huntly B, Spring D, Skjoedt M, Skjødt K, de la Roche M, de la Roche M. Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Molecular Medicine 2024, 16: 2233-2261. PMID: 39169164, PMCID: PMC11393416, DOI: 10.1038/s44321-024-00121-2.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaColorectal cancerTarget multiple cancer typesBispecific T-cell engagerCell killing in vitroChimeric antigen receptorT-cell engagersCancer cells in vitroPre-B-ALLAnti-tumor efficacyCancer cell killing in vitroKilling in vitroCells in vitroAntibody-drug conjugatesMultiple cancer typesLGR5 overexpressionTumor burdenAntigen receptorMurine modelNovel immunotherapeuticsCancer modelsTumor cellsEffective modalityEffective tumorLgr5Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/Refractory Multiple MyelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2021
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Owonikoko T, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Sadraei N, Shetty A, Smit M, Zhang Y, Sable B, Pati A, Roy S, Borghaei H. OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC. Journal Of Thoracic Oncology 2021, 16: s126. DOI: 10.1016/j.jtho.2021.01.313.Peer-Reviewed Original ResearchBispecific T-cell engagerT-cell engagers
2015
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
Xu Y, Hijazi Y, Wolf A, Wu B, Sun Y, Zhu M. Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. CPT Pharmacometrics & Systems Pharmacology 2015, 4: 507-515. PMID: 26451330, PMCID: PMC4592530, DOI: 10.1002/psp4.12003.Peer-Reviewed Original ResearchElevation of cytokinesCytokine elevationCD19/CD3 bispecific T-cell engagerIL-6-mediated changesBispecific T-cell engagerIL-6T-cell engagersSuppression of CYP3A4Treatment of leukemiaSubstrates of CYP3A4Blinatumomab infusionCYP2C9 activityCytokine cocktailTransient elevationMagnitude of suppressionDrug interactionsCytochrome P450 enzyme activityCYP450 activityCytokinesPharmacokinetic modelHuman hepatocytesBlinatumomabPBPK modelCYP2C9Enzyme activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply